Cargando…

Harnessing preclinical models for the interrogation of ovarian cancer

Ovarian cancer (OC) is a heterogeneous malignancy with various etiology, histopathology, and biological feature. Despite accumulating understanding of OC in the post-genomic era, the preclinical knowledge still undergoes limited translation from bench to beside, and the prognosis of ovarian cancer h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Tianyu, Fan, Junpeng, Lu, Funian, Zhang, Li, Liu, Chen, Xiong, Qiyue, Zhao, Yang, Chen, Gang, Sun, Chaoyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479310/ https://www.ncbi.nlm.nih.gov/pubmed/36114548 http://dx.doi.org/10.1186/s13046-022-02486-z

Ejemplares similares

Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis
por: Yang, Bin, et al.
Publicado: (2022)

MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC
por: Zhuang, Xucui, et al.
Publicado: (2023)

Harnessing Tissue Engineering Tools to Interrogate Host-Microbiota Crosstalk in Cancer
por: Udayasuryan, Barath, et al.
Publicado: (2020)

STAT4, a potential predictor of prognosis, promotes CD8 T‑cell infiltration in ovarian serous carcinoma by inducing CCL5 secretion
por: Wang, Wei, et al.
Publicado: (2023)

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer
por: Liu, Chen, et al.
Publicado: (2022)

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma
por: Hu, Dianxing, et al.
Publicado: (2022)

Harnessing (13)C-labeled myo-inositol to interrogate inositol phosphate messengers by NMR
por: Harmel, Robert K., et al.
Publicado: (2019)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection
por: Yang, Bin, et al.
Publicado: (2021)

Drug screening model meets cancer organoid technology
por: Liu, Chen, et al.
Publicado: (2020)

Mouse models of epithelial ovarian cancer for preclinical studies
por: Karakashev, Sergey, et al.
Publicado: (2021)

The clinical potential of optogenetic interrogation of pathogenesis
por: Gao, Tianyu Terry, et al.
Publicado: (2023)

Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer
por: Huang, Yuhan, et al.
Publicado: (2023)

Metagenomic analysis of the microbiome of the upper reproductive tract: combating ovarian cancer through predictive, preventive, and personalized medicine
por: Qin, Xu, et al.
Publicado: (2022)

Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism
por: Bose, Shree, et al.
Publicado: (2022)

Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer
por: Xiao, Rourou, et al.
Publicado: (2022)

Functional Interrogation of Enhancer Connectome Prioritizes Candidate Target Genes at Ovarian Cancer Susceptibility Loci
por: Wang, Wei, et al.
Publicado: (2021)

Xenotransplantation: Current Status in Preclinical Research
por: Lu, Tianyu, et al.
Publicado: (2020)

Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer
por: Porru, Manuela, et al.
Publicado: (2020)

Interrogating the real /
por: Žižek, Slavoj
Publicado: (2006)

The Interrogation Mark
por: Brooke, Margaret C.
Publicado: (1925)

Preclinical humanized mouse model with ectopic ovarian tissues
por: FU, SHILONG, et al.
Publicado: (2014)

Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer
por: Blagden, Sarah P.
Publicado: (2015)

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

Interrogating the architecture of cancer genomes
por: Campbell, Peter
Publicado: (2011)

Six Gynecological Cancer Patients Infected With SARS-CoV-2 After Surgery or Radio-/Chemo-Therapy Treatment: Case Series
por: Liu, Chen, et al.
Publicado: (2020)

Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer
por: Wall, Jaclyn A., et al.
Publicado: (2020)

Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models
por: Maenhoudt, Nina, et al.
Publicado: (2020)

Interrogatives about neutrinos
por: Pontecorvo, B M
Publicado: (1972)

Interrogating personhood and dementia
por: Higgs, Paul, et al.
Publicado: (2016)

Interrogative suggestibility in the elderly
por: Biondi, Silvia, et al.
Publicado: (2020)

Microwave Wire Interrogation Method Mapping Pressure under High Temperatures
por: Chen, Xiaoyong, et al.
Publicado: (2017)

Harnessing the Power of Optical Microscopic and Macroscopic Imaging for Natural Products as Cancer Therapeutics
por: Yan, Tianyu, et al.
Publicado: (2019)

WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway
por: Guo, Ensong, et al.
Publicado: (2021)

Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
por: Heo, Eun Jin, et al.
Publicado: (2017)

Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer’s disease
por: Sundaram, Guruswami SM, et al.
Publicado: (2015)

Patient-Derived Xenografts Are a Reliable Preclinical Model for the Personalized Treatment of Epithelial Ovarian Cancer
por: Chen, Jiayu, et al.
Publicado: (2021)

Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy
por: Yan, Liang, et al.
Publicado: (2021)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Progesterone and FOXO1 signaling: Harnessing cellular senescence for the treatment of ovarian cancer
por: Brosens, Jan J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pcnt2agcblmsscd37pabkkettq